Unknown PHASE3 INTERVENTIONAL 1-arm NCT04289103

Evaluation of EFficacy and SaFEty of Leukotac (Inolimomab) in Pediatric Patients With SR-aGvHD (EiFFEL)

A Phase 3, Multicenter, Open Label, Study to Evaluate the EFficacy and SaFEty of Leukotac® (Inolimomab) in Pediatric Patients With Steroid Resistant Acute Graft Versus Host Disease (SR-aGvHD)

Sponsor: ElsaLys Biotech

Conditions Steroid Refractory GVHD

Interventions Inolimomab (Leukotac)

Updated 4 times since 2020 Last updated: Dec 15, 2020 Started: Oct 31, 2021 Primary completion: Dec 31, 2022 Completion: Jun 30, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Steroid Refractory GVHD and is currently ongoing. ElsaLys Biotech leads this study, which shows 4 recorded versions since 2021 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE3
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE3

Status: Not Yet Recruiting → Unknown
Jan 2021 — Jul 2024 [monthly]

Not Yet Recruiting PHASE3
Mar 2020 — Jan 2021 [monthly]

Not Yet Recruiting PHASE3

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

ElsaLys Biotech

Data source: ElsaLys Biotech

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.